Genesis Biopharma appoints new ceo and cfo

Anthony Cataldo and Michael Handelman also join board of directors

Genesis Biopharma, a US biotechnology company developing targeted cancer therapies, has named Anthony Cataldo as president and chief executive. He succeeds Robert Brooke, who is now a strategic advisor to the Manhattan Beach, California-based company.

In addition Genesis Biopharma has appointed Michael Handelman as chief financial officer, treasurer and secretary, succeeding Richard McKilligan.

Cataldo and Handelman have joined the company's Board, while Brooke, McKilligan and Mark Ahn have resigned as members.

‘I'm looking forward to working with the Genesis Biopharma board to further the progress of our important cancer technology, and to develop new strategic opportunities to build shareholder value,’ said Cataldo.

‘Genesis Biopharma's targeted anti-CD55 monoclonal antibody technology has widespread clinical utility, as it neutralises a key cancer defence mechanism that is over-expressed in more than 80% of tumours. It could provide a safe alternative to toxic chemotherapy regimens, and has the potential to expand and improve the clinical utility of already approved antibody therapies as well as some novel agents in development.’

Cataldo was formerly chairman, chief executive and a director of Oxis International. Prior to this he was non-executive co-chairman of the Board of MultiCell Technologies.

Handelman was chief financial officer of Oxis International. Prior to this he was cfo and coo of TechnoConcepts.

You may also like

Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Ingredients

Meet Navetta: new approach to safety testing of drugs and particles

Turn inhalation research upside down
Subscribe now